PedAM
Pediatric Disease Annotations & Medicines
| gastroenteritis | ||||
| Disease ID | 895 |
|---|---|
| Disease | gastroenteritis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:13) C0011991 | diarrhea | 27 C0011175 | dehydration | 24 C0009951 | convulsions | 23 C0042963 | vomiting | 22 C0035869 | rotavirus infection | 7 C0004610 | bacteremia | 4 C0009952 | febrile seizures | 4 C0022660 | acute renal failure | 3 C0008354 | cholera | 1 C0022951 | lactose intolerance | 1 C0030446 | paralytic ileus | 1 C0042963 | emesis | 1 C0020625 | hyponatremia | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:6) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0017160 | colchicine | D003078 | 64-86-8 | gastroenteritis | MESH:D005759 | marker/mechanism | 843157 | ||
| C0017160 | erythromycin | D004917 | 114-07-8 | gastroenteritis | MESH:D005759 | marker/mechanism | 9326871 | ||
| C0017160 | fluorouracil | D005472 | 51-21-8 | gastroenteritis | MESH:D005759 | marker/mechanism | 6603024 | ||
| C0017160 | fluoxetine | D005473 | 54910-89-3 | gastroenteritis | MESH:D005759 | marker/mechanism | 11078032 | ||
| C0017160 | methotrexate | D008727 | 1959/5/2 | gastroenteritis | MESH:D005759 | marker/mechanism | 6603024 | ||
| C0017160 | nitric oxide | D009569 | 10102-43-9 | gastroenteritis | MESH:D005759 | marker/mechanism | 12682265 | ||
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D005759 | inomax | nitric oxide | 100PPM Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | GAS;INHALATION | Discontinued | None | Yes | No |
FDA labeling changes(Total Drugs:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D005759 | 12/21/2010 | inomax | nitric oxide | Prevention of bronchopulmonary dysplasia | INOmax is not indicated for prevention of BPD in preterm neonates d 34 weeks gestational age.Efficacy for the prevention of BPD in preterm infants was not established in three ldouble-blind, placebo-controlled clinical trials in a total of 2,149 preterm infants Information on clinical trials, adverse reaction | Labeling | B | - | - | - | INO Therapeutics | 2/11/2010 | FALSE' |